Currently browsing tag


Lilly’s psoriatic arthritis drug succeeds in late-stage study

(Reuters) – Eli Lilly and Co said its experimental drug, ixekizumab, was more effective than a placebo in patients with active psoriatic arthritis, in a late-stage trial. Psoriatic arthritis is a progressive and chronic disease that can cause swelling, stiffness and pain in and around joints. (Reporting by Natalie Grover in Bengaluru; Editing by Savio D’Souza)